Giuliano Tocci, Giulia Nardoianni, Barbara Pala, Barbara Citoni, Agostino Virdis, Maria Lorenza Muiesan, Guido Grassi, Emanuele Barbato, Massimo Volpe
{"title":"2024年欧洲心脏病学会高血压指南后正常血压水平患者的重新分类","authors":"Giuliano Tocci, Giulia Nardoianni, Barbara Pala, Barbara Citoni, Agostino Virdis, Maria Lorenza Muiesan, Guido Grassi, Emanuele Barbato, Massimo Volpe","doi":"10.1097/HJH.0000000000004140","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In 2024, the European Society of Cardiology (ESC) guidelines proposed a new classification of elevated blood pressure (BP) and hypertension.</p><p><strong>Aim: </strong>To evaluate how many individuals with optimal, normal, and high-normal BP, as defined by the 2023 European Society of Hypertension (ESH) guidelines, would be reclassified as not-elevated or elevated BP, according to the new ESC guidelines.</p><p><strong>Methods: </strong>In this single-center, observational, retrospective, cohort study, we included adult individuals who were consecutively evaluated for home, office, and ambulatory BP measurements, and global cardiovascular risk stratification. All patients underwent BP measurements using a validated, oscillometric, automatic device (Mobil-O-Graph PWA Monitor, I.E.M. GmbH, Stolberg, Germany). Only untreated individuals with office BP levels <140/<90 mmHg and without comorbidities were considered for the analysis. Selected population was stratified according to 2023 ESH (optimal BP, <120/<80 mmHg; normal BP, 120-129/80-84 mmHg; high-normal BP, 130-139/85-89 mmHg) and then reclassified according to 2024 ESC guidelines (not-elevated BP, <120/<70 mmHg; elevated BP, 120-139/70-89 mmHg). Home and 24-h ambulatory BP levels were also evaluated in each category, when available.</p><p><strong>Results: </strong>We analysed 1230 adult untreated individuals with valid office BP levels, among whom 89.0% also had ambulatory and 42.6% home BP data, respectively. According to 2023 ESH guidelines, 262 (21.3%) individuals had optimal, 375 (30.5%) normal, and 593 (48.2%) high-normal BP levels; according to 2024 ESC guidelines, 87 (7.1%) had nonelevated, and 1143 (92.9%) had elevated BP. Compared to 2023 ESH guidelines, 66.8% individuals with optimal BP, and all individuals (100.0%) with normal and high-normal BP levels were reclassified as elevated BP by adopting 2024 ESC guidelines. This shift is more evident in women than in men (67.2 vs. 65.8%; P < 0.001).</p><p><strong>Conclusion: </strong>According to 2024 ESC guidelines, most individuals with optimal, and all those with normal and high-normal BP levels, as defined by 2023 ESH guidelines, are reclassified in the elevated BP category.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reclassification of patients with normal blood pressure levels after 2024 European society of cardiology guidelines on hypertension.\",\"authors\":\"Giuliano Tocci, Giulia Nardoianni, Barbara Pala, Barbara Citoni, Agostino Virdis, Maria Lorenza Muiesan, Guido Grassi, Emanuele Barbato, Massimo Volpe\",\"doi\":\"10.1097/HJH.0000000000004140\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In 2024, the European Society of Cardiology (ESC) guidelines proposed a new classification of elevated blood pressure (BP) and hypertension.</p><p><strong>Aim: </strong>To evaluate how many individuals with optimal, normal, and high-normal BP, as defined by the 2023 European Society of Hypertension (ESH) guidelines, would be reclassified as not-elevated or elevated BP, according to the new ESC guidelines.</p><p><strong>Methods: </strong>In this single-center, observational, retrospective, cohort study, we included adult individuals who were consecutively evaluated for home, office, and ambulatory BP measurements, and global cardiovascular risk stratification. All patients underwent BP measurements using a validated, oscillometric, automatic device (Mobil-O-Graph PWA Monitor, I.E.M. GmbH, Stolberg, Germany). Only untreated individuals with office BP levels <140/<90 mmHg and without comorbidities were considered for the analysis. Selected population was stratified according to 2023 ESH (optimal BP, <120/<80 mmHg; normal BP, 120-129/80-84 mmHg; high-normal BP, 130-139/85-89 mmHg) and then reclassified according to 2024 ESC guidelines (not-elevated BP, <120/<70 mmHg; elevated BP, 120-139/70-89 mmHg). Home and 24-h ambulatory BP levels were also evaluated in each category, when available.</p><p><strong>Results: </strong>We analysed 1230 adult untreated individuals with valid office BP levels, among whom 89.0% also had ambulatory and 42.6% home BP data, respectively. According to 2023 ESH guidelines, 262 (21.3%) individuals had optimal, 375 (30.5%) normal, and 593 (48.2%) high-normal BP levels; according to 2024 ESC guidelines, 87 (7.1%) had nonelevated, and 1143 (92.9%) had elevated BP. Compared to 2023 ESH guidelines, 66.8% individuals with optimal BP, and all individuals (100.0%) with normal and high-normal BP levels were reclassified as elevated BP by adopting 2024 ESC guidelines. This shift is more evident in women than in men (67.2 vs. 65.8%; P < 0.001).</p><p><strong>Conclusion: </strong>According to 2024 ESC guidelines, most individuals with optimal, and all those with normal and high-normal BP levels, as defined by 2023 ESH guidelines, are reclassified in the elevated BP category.</p>\",\"PeriodicalId\":16043,\"journal\":{\"name\":\"Journal of Hypertension\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hypertension\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/HJH.0000000000004140\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/HJH.0000000000004140","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
摘要
2024年,欧洲心脏病学会(ESC)指南提出了高血压和高血压的新分类。目的:根据新的ESC指南,评估2023年欧洲高血压学会(ESH)指南中定义的最佳、正常和高正常血压患者中有多少人将被重新分类为血压不升高或升高。方法:在这项单中心、观察性、回顾性、队列研究中,我们纳入了成年个体,对他们进行了连续的家庭、办公室和动态血压测量和全球心血管风险分层评估。所有患者均使用经过验证的振荡自动装置(mobilo - o - graph PWA监测仪,I.E.M. GmbH, Stolberg,德国)进行血压测量。结果:我们分析了1230名未接受治疗的有效办公室血压水平的成年个体,其中89.0%的人有门诊血压数据,42.6%的人有家庭血压数据。根据2023年ESH指南,262人(21.3%)血压最佳,375人(30.5%)血压正常,593人(48.2%)血压高正常;根据2024年ESC指南,87例(7.1%)血压未升高,1143例(92.9%)血压升高。与2023年ESH指南相比,采用2024年ESC指南后,66.8%的最佳血压个体以及所有正常和高正常血压个体(100.0%)被重新归类为血压升高。结论:根据2024年ESC指南,根据2023年ESH指南的定义,大多数血压处于最佳水平的个体,以及所有血压正常和高正常水平的个体,都被重新归类为血压升高类别。
Reclassification of patients with normal blood pressure levels after 2024 European society of cardiology guidelines on hypertension.
Introduction: In 2024, the European Society of Cardiology (ESC) guidelines proposed a new classification of elevated blood pressure (BP) and hypertension.
Aim: To evaluate how many individuals with optimal, normal, and high-normal BP, as defined by the 2023 European Society of Hypertension (ESH) guidelines, would be reclassified as not-elevated or elevated BP, according to the new ESC guidelines.
Methods: In this single-center, observational, retrospective, cohort study, we included adult individuals who were consecutively evaluated for home, office, and ambulatory BP measurements, and global cardiovascular risk stratification. All patients underwent BP measurements using a validated, oscillometric, automatic device (Mobil-O-Graph PWA Monitor, I.E.M. GmbH, Stolberg, Germany). Only untreated individuals with office BP levels <140/<90 mmHg and without comorbidities were considered for the analysis. Selected population was stratified according to 2023 ESH (optimal BP, <120/<80 mmHg; normal BP, 120-129/80-84 mmHg; high-normal BP, 130-139/85-89 mmHg) and then reclassified according to 2024 ESC guidelines (not-elevated BP, <120/<70 mmHg; elevated BP, 120-139/70-89 mmHg). Home and 24-h ambulatory BP levels were also evaluated in each category, when available.
Results: We analysed 1230 adult untreated individuals with valid office BP levels, among whom 89.0% also had ambulatory and 42.6% home BP data, respectively. According to 2023 ESH guidelines, 262 (21.3%) individuals had optimal, 375 (30.5%) normal, and 593 (48.2%) high-normal BP levels; according to 2024 ESC guidelines, 87 (7.1%) had nonelevated, and 1143 (92.9%) had elevated BP. Compared to 2023 ESH guidelines, 66.8% individuals with optimal BP, and all individuals (100.0%) with normal and high-normal BP levels were reclassified as elevated BP by adopting 2024 ESC guidelines. This shift is more evident in women than in men (67.2 vs. 65.8%; P < 0.001).
Conclusion: According to 2024 ESC guidelines, most individuals with optimal, and all those with normal and high-normal BP levels, as defined by 2023 ESH guidelines, are reclassified in the elevated BP category.
期刊介绍:
The Journal of Hypertension publishes papers reporting original clinical and experimental research which are of a high standard and which contribute to the advancement of knowledge in the field of hypertension. The Journal publishes full papers, reviews or editorials (normally by invitation), and correspondence.